MEDVi Examined: Is It Legit? Benefits, Safety, Complaints, and Customer Feedback

A new telehealth platform aims to provide physician-supervised GLP-1 weight loss therapy, but raises questions about compounded drugs and regulatory oversight.

Published on Feb. 8, 2026

Got story updates? Submit your updates here. ›

MEDVi is a telehealth service that connects patients with licensed clinicians to receive GLP-1 weight loss therapy, including prescriptions for compounded semaglutide or tirzepatide medications dispensed by U.S. licensed pharmacy partners. The platform emphasizes physician oversight and medical supervision, but also faces questions around the use of compounded drugs and regulatory transparency.

Why it matters

Weight management remains a significant challenge in the U.S., and new digital-first approaches like MEDVi aim to improve access to medically-supervised weight loss treatments. However, the use of compounded GLP-1 medications and the platform's role in the treatment process raise concerns about safety, efficacy, and regulatory oversight.

The details

MEDVi operates as a telehealth service that links patients with licensed clinicians to receive GLP-1 weight loss therapy. Patients undergo a virtual health assessment, and if deemed appropriate for treatment, can receive prescriptions for compounded semaglutide or tirzepatide medications from U.S. licensed pharmacy partners. MEDVi emphasizes physician oversight, with clinicians making all treatment decisions, but the platform does not directly provide diagnosis, prescriptions or treatment management.

  • MEDVi was launched in 2026.

The players

MEDVi

A telehealth platform that facilitates access to physician-supervised GLP-1 weight loss therapy, including prescriptions for compounded medications.

Got photos? Submit your photos here. ›

What’s next

As MEDVi continues to grow, regulators and medical experts will likely scrutinize the platform's use of compounded GLP-1 medications and its overall transparency around the clinician's role in the treatment process.

The takeaway

MEDVi represents a new digital-first approach to weight management, leveraging telehealth to improve access to physician-supervised GLP-1 therapy. However, the platform's reliance on compounded drugs and its positioning as a facilitator rather than a direct provider of care raise important questions about safety, efficacy and regulatory oversight that will need to be addressed.